fcγriib

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].

2141-V11 is an anti-CD40 agonist antibody that is enhanced by binding to FcγRIIB. In vivo, 2141-V11 can initiate an effective tumor-specific T-cell response and is applicable in the study of BCG-unresponsive non-muscle-invasive bladder cancer.

SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. It enhances binding to activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT is applicable for research in advanced solid tumors and lymphomas.

BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcγRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC).

ADG-106 is a fully human monoclonal antibody targeting CD137 (4-1BB). It activates CD137 via potent FcγRIIB-mediated cross-linking, antagonising CD137 ligands, and may be employed for anti-tumour immunotherapy.

MGD010 is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. By simultaneously co-engaging CD32B (FcγRIIb) and the BCR component CD79B, MGD010 delivers an inhibitory signal, thereby suppressing activated B cells. MGD010 shows potential for research in autoimmune diseases.

BI-1206 represents a highly specialized antagonistic monoclonal antibody specifically engineered to target the human inhibitory Fc gamma receptor IIB with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of receptor-mediated internalization of therapeutic antibodies across various preclinical experimental models to evaluate the enhancement of antibody-dependent cellular cytotoxicity in specialized oncology research environments.